149 related articles for article (PubMed ID: 36884224)
1. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
Baumrin E; Shin DB; Mitra N; Pidala J; El Jurdi N; Lee SJ; Loren AW; Gelfand JM
JAMA Dermatol; 2024 Apr; 160(4):393-401. PubMed ID: 38416506
[TBL] [Abstract][Full Text] [Related]
3. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease.
Cardones AR; Sullivan KM; Green C; Chao NJ; Rowe-Nichols K; Bañez LL; Burton CS; Horwitz ME; Long GD; Rao CL; Sarantopoulos S; Sidhu-Malik N; Sung AD; Hall RP
JAMA Dermatol; 2019 Jul; 155(7):833-837. PubMed ID: 30994873
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
5. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
6. Frailty in Patients with Chronic Graft-versus-Host Disease.
Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
[TBL] [Abstract][Full Text] [Related]
7. The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.
Gandelman JS; Zic J; Dewan AK; Lee SJ; Flowers M; Cutler C; Pidala J; Chen H; Jagasia MH; Tkaczyk ER
Biol Blood Marrow Transplant; 2019 Feb; 25(2):279-286. PubMed ID: 30219700
[TBL] [Abstract][Full Text] [Related]
8. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
DeFilipp Z; Alousi AM; Pidala JA; Carpenter PA; Onstad LE; Arai S; Arora M; Cutler CS; Flowers MED; Kitko CL; Chen GL; Lee SJ; Hamilton BK
Blood Adv; 2021 Oct; 5(20):4278-4284. PubMed ID: 34521116
[TBL] [Abstract][Full Text] [Related]
9. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes.
Novitzky-Basso I; AlHayli S; Shin E; Pasic I; Al-Shaibani Z; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Eur J Haematol; 2021 Apr; 106(4):508-519. PubMed ID: 33421199
[TBL] [Abstract][Full Text] [Related]
10. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
11. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
12. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
Mitchell SA; Jacobsohn D; Thormann Powers KE; Carpenter PA; Flowers ME; Cowen EW; Schubert M; Turner ML; Lee SJ; Martin P; Bishop MR; Baird K; Bolaños-Meade J; Boyd K; Fall-Dickson JM; Gerber LH; Guadagnini JP; Imanguli M; Krumlauf MC; Lawley L; Li L; Reeve BB; Clayton JA; Vogelsang GB; Pavletic SZ
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1619-29. PubMed ID: 21536143
[TBL] [Abstract][Full Text] [Related]
13. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
[TBL] [Abstract][Full Text] [Related]
14. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide.
Arora S; Thakkar D; Upasana K; Yadav A; Rastogi N; Sharma PS; Yadav SP
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e44-e50. PubMed ID: 37983773
[TBL] [Abstract][Full Text] [Related]
16. Oral disease profiles in chronic graft versus host disease.
Bassim CW; Fassil H; Mays JW; Edwards D; Baird K; Steinberg SM; Cowen EW; Naik H; Datiles M; Stratton P; Gress RE; Pavletic SZ
J Dent Res; 2015 Apr; 94(4):547-54. PubMed ID: 25740857
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
18. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
19. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DD
Ann Hematol; 2017 May; 96(5):805-815. PubMed ID: 28214979
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
Palmer J; Williams K; Inamoto Y; Chai X; Martin PJ; Tomas LS; Cutler C; Weisdorf D; Kurland BF; Carpenter PA; Pidala J; Pavletic SZ; Wood W; Jacobsohn D; Arai S; Arora M; Jagasia M; Vogelsang GB; Lee SJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):337-44. PubMed ID: 24315845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
